Cargando…

Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines

Objectives. This study was aimed to determine the therapeutic principle and identify Chinese Patent Medicine (CPM) with corresponding indications for hypertension treatment. Methods. Three rounds of Delphi survey were mailed among 40 cardiovascular integrative medicine specialists. Items with agreem...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li Ying, Chan, Kam Wa, Yuwen, Ya, Shi, Nan Nan, Han, Xue Jie, Lu, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638588/
https://www.ncbi.nlm.nih.gov/pubmed/23662141
http://dx.doi.org/10.1155/2013/510146
_version_ 1782475847635042304
author Wang, Li Ying
Chan, Kam Wa
Yuwen, Ya
Shi, Nan Nan
Han, Xue Jie
Lu, Aiping
author_facet Wang, Li Ying
Chan, Kam Wa
Yuwen, Ya
Shi, Nan Nan
Han, Xue Jie
Lu, Aiping
author_sort Wang, Li Ying
collection PubMed
description Objectives. This study was aimed to determine the therapeutic principle and identify Chinese Patent Medicine (CPM) with corresponding indications for hypertension treatment. Methods. Three rounds of Delphi survey were mailed among 40 cardiovascular integrative medicine specialists. Items with agreement of more than 80% respondents were included in the consensus. Results. According to majority of the panelists, CPM is suitable for most hypertensive patients and should be used according to traditional Chinese medicine pattern classification. CPM could be used alone for grade 1 hypertension and could be used in combination with Western biomedicine (WM) for both grade 2 and grade 3 hypertension. It is recommended that less than two CPMs are used simultaneously. For the treatment of grade 2 and 3 hypertension, CPM and WM should be taken separately. Recommended CPMs included Tianma Gouteng granule, Qiju Dihuang capsule, Jinkui Shenqi pill, Yinxingye tablet, Niuhuang Jiangya pill and Banxia Tianma pill. The indications of 4 CPMs were specified with symptoms related to TCM pattern classification by the experts. Conclusions. An expert consensus on CMP application was formed for the treatment of hypertension in the form of integrative medicine. A flow of IM hypertension management was proposed based on the results of the survey.
format Online
Article
Text
id pubmed-3638588
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36385882013-05-09 Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines Wang, Li Ying Chan, Kam Wa Yuwen, Ya Shi, Nan Nan Han, Xue Jie Lu, Aiping Evid Based Complement Alternat Med Research Article Objectives. This study was aimed to determine the therapeutic principle and identify Chinese Patent Medicine (CPM) with corresponding indications for hypertension treatment. Methods. Three rounds of Delphi survey were mailed among 40 cardiovascular integrative medicine specialists. Items with agreement of more than 80% respondents were included in the consensus. Results. According to majority of the panelists, CPM is suitable for most hypertensive patients and should be used according to traditional Chinese medicine pattern classification. CPM could be used alone for grade 1 hypertension and could be used in combination with Western biomedicine (WM) for both grade 2 and grade 3 hypertension. It is recommended that less than two CPMs are used simultaneously. For the treatment of grade 2 and 3 hypertension, CPM and WM should be taken separately. Recommended CPMs included Tianma Gouteng granule, Qiju Dihuang capsule, Jinkui Shenqi pill, Yinxingye tablet, Niuhuang Jiangya pill and Banxia Tianma pill. The indications of 4 CPMs were specified with symptoms related to TCM pattern classification by the experts. Conclusions. An expert consensus on CMP application was formed for the treatment of hypertension in the form of integrative medicine. A flow of IM hypertension management was proposed based on the results of the survey. Hindawi Publishing Corporation 2013 2013-04-03 /pmc/articles/PMC3638588/ /pubmed/23662141 http://dx.doi.org/10.1155/2013/510146 Text en Copyright © 2013 Li Ying Wang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Li Ying
Chan, Kam Wa
Yuwen, Ya
Shi, Nan Nan
Han, Xue Jie
Lu, Aiping
Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines
title Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines
title_full Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines
title_fullStr Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines
title_full_unstemmed Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines
title_short Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines
title_sort expert consensus on the treatment of hypertension with chinese patent medicines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638588/
https://www.ncbi.nlm.nih.gov/pubmed/23662141
http://dx.doi.org/10.1155/2013/510146
work_keys_str_mv AT wangliying expertconsensusonthetreatmentofhypertensionwithchinesepatentmedicines
AT chankamwa expertconsensusonthetreatmentofhypertensionwithchinesepatentmedicines
AT yuwenya expertconsensusonthetreatmentofhypertensionwithchinesepatentmedicines
AT shinannan expertconsensusonthetreatmentofhypertensionwithchinesepatentmedicines
AT hanxuejie expertconsensusonthetreatmentofhypertensionwithchinesepatentmedicines
AT luaiping expertconsensusonthetreatmentofhypertensionwithchinesepatentmedicines